Metalloproteases as potential therapeutic targets in arthritis treatment

Andrew D Rowan, Gary J Litherland, Wang Hui, Jennifer M Milner

Research output: Contribution to journalArticle

Abstract

Dysregulated proteolysis of the extracellular matrix of articular cartilage represents a unifying hallmark of the arthritides, and has been a target for therapeutic intervention for some time, although clinical efficacy has been elusive. Members of the 'A disintegrin and metalloprotease with thrombospondin motifs' and matrix metalloprotease families are considered to be collectively responsible for cartilage catabolism, such that inhibition of these activities is theoretically a highly attractive strategy for preventing further proteolytic damage. This review outlines the biology of these metalloproteases and what we have learnt from inhibition studies and transgenics, and highlights the important questions that this information raises for the future development of therapeutics directed towards metalloproteases for arthritis treatment.

Original languageEnglish
Pages (from-to)1-18
Number of pages18
JournalExpert Opinion on Therapeutic Targets
Volume12
Issue number1
DOIs
Publication statusPublished - Jan 2008
Externally publishedYes

Fingerprint

Metalloproteases
Arthritis
Cartilage
Proteolysis
Thrombospondins
Disintegrins
Articular Cartilage
Therapeutics
Extracellular Matrix

Keywords

  • Animals
  • Arthritis
  • Humans
  • Metalloproteases
  • Protease Inhibitors

Cite this

Rowan, Andrew D ; Litherland, Gary J ; Hui, Wang ; Milner, Jennifer M. / Metalloproteases as potential therapeutic targets in arthritis treatment. In: Expert Opinion on Therapeutic Targets. 2008 ; Vol. 12, No. 1. pp. 1-18.
@article{34a79da1624d43e7932711005bc04f72,
title = "Metalloproteases as potential therapeutic targets in arthritis treatment",
abstract = "Dysregulated proteolysis of the extracellular matrix of articular cartilage represents a unifying hallmark of the arthritides, and has been a target for therapeutic intervention for some time, although clinical efficacy has been elusive. Members of the 'A disintegrin and metalloprotease with thrombospondin motifs' and matrix metalloprotease families are considered to be collectively responsible for cartilage catabolism, such that inhibition of these activities is theoretically a highly attractive strategy for preventing further proteolytic damage. This review outlines the biology of these metalloproteases and what we have learnt from inhibition studies and transgenics, and highlights the important questions that this information raises for the future development of therapeutics directed towards metalloproteases for arthritis treatment.",
keywords = "Animals, Arthritis, Humans, Metalloproteases, Protease Inhibitors",
author = "Rowan, {Andrew D} and Litherland, {Gary J} and Wang Hui and Milner, {Jennifer M}",
year = "2008",
month = "1",
doi = "10.1517/14728222.12.1.1",
language = "English",
volume = "12",
pages = "1--18",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Taylor & Francis",
number = "1",

}

Metalloproteases as potential therapeutic targets in arthritis treatment. / Rowan, Andrew D; Litherland, Gary J; Hui, Wang; Milner, Jennifer M.

In: Expert Opinion on Therapeutic Targets, Vol. 12, No. 1, 01.2008, p. 1-18.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Metalloproteases as potential therapeutic targets in arthritis treatment

AU - Rowan, Andrew D

AU - Litherland, Gary J

AU - Hui, Wang

AU - Milner, Jennifer M

PY - 2008/1

Y1 - 2008/1

N2 - Dysregulated proteolysis of the extracellular matrix of articular cartilage represents a unifying hallmark of the arthritides, and has been a target for therapeutic intervention for some time, although clinical efficacy has been elusive. Members of the 'A disintegrin and metalloprotease with thrombospondin motifs' and matrix metalloprotease families are considered to be collectively responsible for cartilage catabolism, such that inhibition of these activities is theoretically a highly attractive strategy for preventing further proteolytic damage. This review outlines the biology of these metalloproteases and what we have learnt from inhibition studies and transgenics, and highlights the important questions that this information raises for the future development of therapeutics directed towards metalloproteases for arthritis treatment.

AB - Dysregulated proteolysis of the extracellular matrix of articular cartilage represents a unifying hallmark of the arthritides, and has been a target for therapeutic intervention for some time, although clinical efficacy has been elusive. Members of the 'A disintegrin and metalloprotease with thrombospondin motifs' and matrix metalloprotease families are considered to be collectively responsible for cartilage catabolism, such that inhibition of these activities is theoretically a highly attractive strategy for preventing further proteolytic damage. This review outlines the biology of these metalloproteases and what we have learnt from inhibition studies and transgenics, and highlights the important questions that this information raises for the future development of therapeutics directed towards metalloproteases for arthritis treatment.

KW - Animals

KW - Arthritis

KW - Humans

KW - Metalloproteases

KW - Protease Inhibitors

U2 - 10.1517/14728222.12.1.1

DO - 10.1517/14728222.12.1.1

M3 - Article

VL - 12

SP - 1

EP - 18

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 1

ER -